

INVESTOR FACT SHEET



Business Summary

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Pipeline

Oncology –There are 4 current programs in the oncology field in preclinical phase. Cantrixil, targeting cancers restricted to the abdomen and malignant ascites with expected clinical trials to commence mid 2015. Trx-7, prostate cancer in pre clinical research and expected to enter the clinic mid 2015. Trilexium targeting GBM and neural cell derived cancers in pre clinical research and expecting to enter the clinic Q4 2015. The final oncology program is the ATM targeting children's solid tumors and various adult cancers expected to enter the clinic in 2016

Degenerative Diseases– 4 programs in early preclinical stage of development

Autoimmune Diseases– Early stage discovery program

Regenerative Diseases– Early stage discovery program

ASX code	NRT
NASDAQ code	NVGN
Share price (24/11/14)	9 cents
Number of shares	~186m
Market capitalisation	~\$16m
52 week range	30/8cents

History

Established in 1994 and listed on the Australian Securities Exchange September 1994. In 1997 Novogen registered its shares (ADS) to trade on the NASDAQ

Board of Directors

Dr Graham Kelly—Chairman and CEO
John O'Connor—Non Executive Director
Steven Coffey—Non Executive Director
Prof Peter Gunning—Non Executive Director

Company Secretary—Lionel Mateo

Auditors

Grant Thornton Audit Pty Ltd
Level 17, 383 Kent Street
SYDNEY NSW 2000

Share Registry

Computershare Investor Services Pty Ltd
Level 4
60 Carrington St
SYDNEY NSW 2000

Australia

16-18 Edgeworth David Ave
HORNSBY NSW 2077,
Australia
+61 2 9472 4100

United States

T316, 5 Science Park 3rd
Floor
New Haven Connecticut
06511, USA

Analyst Coverage
BBY Limited
Dr Dennis Hulme
+61 2 9226 0083

Corporate Relations USA
Vice-President Corporate Relations
Robert Kennedy
Robert.Kennedy@novogen.com

Corporate Contact
CEO & Chairman
Dr Graham Kelly
Graham.Kelly@novogen.com
+61 2 9472 4100

Media Enquiries
Operations Manager
Cristyn Humphreys
Cristyn.Humphreys@novogen.com
+61 2 9472 4111